Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$99.86
Market cap
$252.61B
P/E Ratio
20.85
Dividend/share
$3.08
EPS
$4.79
Enterprise value
$276.15B
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the
Highlights
The P/E is 91% lower than the last 4 quarters average of 242.6 and 71% lower than the 5-year quarterly average of 70.9
The gross profit has grown by 11% year-on-year
The EPS has soared by 165% YoY but it has contracted by 11% from the previous quarter
The net income has surged by 164% year-on-year but it has declined by 12% since the previous quarter
MRK's debt is up by 9% year-on-year
Key stats
What are the main financial stats of MRK
Market
Valuations
Earnings
Shares outstanding
2.53B
Market cap
$252.61B
Enterprise value
$276.15B
Price to earnings (P/E)
20.85
Price to book (P/B)
5.69
Price to sales (P/S)
4.01
EV/EBIT
18.46
EV/EBITDA
14.36
EV/Sales
4.37
Revenue
$63.17B
EBIT
$14.96B
EBITDA
$19.22B
Free cash flow
$14.84B
Per share
Balance sheet
Liquidity
EPS
$4.79
Free cash flow per share
$5.86
Book value per share
$17.56
Revenue per share
$24.93
TBVPS
$31.11
Total assets
$117.53B
Total liabilities
$72.97B
Debt
$38.13B
Equity
$44.5B
Working capital
$10.78B
Debt to equity
0.86
Current ratio
1.36
Quick ratio
0.88
Net debt/EBITDA
1.22
Margins
Efficiency
Dividend
EBITDA margin
30.4%
Gross margin
75.8%
Net margin
19.2%
Operating margin
21.6%
Return on assets
11%
Return on equity
29.3%
Return on invested capital
20.8%
Return on capital employed
17%
Return on sales
23.7%
Dividend yield
3.08%
DPS
$3.08
Payout ratio
64.3%
MRK stock price
How has the Merck stock price performed over time
Intraday
2.48%
1 week
1.53%
1 month
-6.09%
1 year
-2.3%
YTD
-8.4%
QTD
-12.06%
Financial performance
How have Merck's revenue and profit performed over time
Revenue
$63.17B
Gross profit
$47.9B
Operating income
$13.65B
Net income
$12.15B
Gross margin
75.8%
Net margin
19.2%
The net income has surged by 164% year-on-year but it has declined by 12% since the previous quarter
MRK's net margin has surged by 146% year-on-year but it is down by 13% since the previous quarter
Merck's operating income has soared by 76% YoY but it has decreased by 12% from the previous quarter
Merck's operating margin has surged by 65% YoY but it has decreased by 13% QoQ
Growth
What is Merck's growth rate over time
Valuation
What is Merck stock price valuation
P/E
20.85
P/B
5.69
P/S
4.01
EV/EBIT
18.46
EV/EBITDA
14.36
EV/Sales
4.37
The EPS has soared by 165% YoY but it has contracted by 11% from the previous quarter
The P/E is 91% lower than the last 4 quarters average of 242.6 and 71% lower than the 5-year quarterly average of 70.9
The price to book (P/B) is 22% lower than the last 4 quarters average of 7.3 and 14% lower than the 5-year quarterly average of 6.6
Merck's equity has increased by 8% YoY and by 2.1% from the previous quarter
MRK's P/S is 18% below its last 4 quarters average of 4.9 and 15% below its 5-year quarterly average of 4.7
The revenue has grown by 7% YoY
Efficiency
How efficient is Merck business performance
Merck's ROE has soared by 174% YoY but it has decreased by 13% from the previous quarter
The company's return on assets has surged by 156% YoY but it fell by 13% QoQ
The ROS has soared by 66% YoY but it has contracted by 10% from the previous quarter
The ROIC has soared by 64% YoY but it fell by 10% QoQ
Dividends
What is MRK's dividend history
DPS
$3.08
Dividend yield
3.08%
Payout ratio
64.3%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Merck financials performed over time
The total assets is 61% more than the total liabilities
Merck's total liabilities has increased by 12% YoY and by 6% QoQ
The total assets has grown by 10% YoY and by 4.4% from the previous quarter
MRK's debt is 14% smaller than its equity
MRK's debt is up by 9% year-on-year
Merck's equity has increased by 8% YoY and by 2.1% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.